



April 21, 2021

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-3525-4707

Launch of the Interstitial cystitis “Zymso[®] Intravesical Solution 50%”

TOKYO, Japan (April 21, 2021) —Kyorin Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President: Shigeru Ogihara, hereinafter "KYORIN "), a wholly owned subsidiary of KYORIN Holdings, Inc., launched the Interstitial cystitis “Zymso[®] Intravesical Solution 50%” (hereinafter “Zymso”) today (April 21).

Interstitial cystitis is a disease that presents with frequent, increased, urgent urination and bladder pain. Among them, bladder pain that occurs when the bladder is full is a characteristic symptom. Persistent symptoms greatly interfere with the patient's daily life and lead to a significant decrease in QOL. A survey in 2013 reported that the number of patients under treatment in Japan was about 4,500, making it one of the orphan diseases.

Clinical Guideline for Interstitial Cystitis/Bladder Pain Syndrome issued in 2019, includes conservative treatment, drug treatment, intravesical instillation therapy, and endoscopic treatment etc. But there is no established treatment as recommended grade A (highly recommended). In addition, at present, the only treatment method covered by health insurance in Japan is bladder hydrodistension, therefore treatment option under health insurance is limited.

KYORIN adds Zymso to its product lineup as a new treatment option for interstitial cystitis in the urology field, which is a priority therapeutic area for KYORIN. By providing the latest information, KYORIN further contributes to the treatment and QOL improvement for patients with interstitial cystitis.

The sales forecast of “Zymso” will be incorporated into the consolidated forecast for the fiscal year ending March 31, 2022 and will be announced when the financial results are announced on May 11, 2021(scheduled).

※ Yamada Y, Nomiya A, Niimi A, Igawa Y, Ito T, Tomoe H, et al. A survey on clinical practice of interstitial cystitis in Japan. *Transl Androl Urol.* 2015; 4(5): 486-90.

(Product Information)

Brand name	Zymso® Intravesical Solution 50%
Generic name	Dimethyl Sulfoxide
Indications	Improvement of symptoms of interstitial cystitis (Hunner type) (chronic pelvic pain, pressure and discomfort associated with the bladder, lower urinary tract symptoms such as increased urgency or pollakiuria)
Dosage and Administration	The usual dosage for adults is 50 mL of 50% (w / w) dimethyl sulfoxide solution per vial (27g as dimethyl sulfoxide) instilled into the bladder 6 times at 2-week intervals. After intravesical injection, hold it in the bladder for at least 15 minutes before draining it.
NHI price	¥11,210.50
Date of approval of manufacturing and marketing	January 22, 2021
Date of Drug Price Listing	April 21, 2021
Date of Launch in Japan	April 21, 2021
Manufacturer and seller	KYORIN Pharmaceutical Co., Ltd.

(Picture)

